<DOC>
	<DOCNO>NCT02260544</DOCNO>
	<brief_summary>Bioequivalence study propose carried patient ovarian cancer , already receive opinion treat physician candidate Doxorubicin liposomal injection therapy .</brief_summary>
	<brief_title>Bioequivalence Study Doxorubicin Hydrochloride Liposome Injection</brief_title>
	<detailed_description>This study sequential two stage design . Bioequivalence base encapsulate doxorubicin test end stage 1 . Power analysis perform primary pharmacokinetic parameter free Doxorubicin liposome encapsulate Doxorubicin , complete patient bioequivalence evaluation . If observed power &gt; = 80 % two one-sided 90 % CI calculate bioequivalence assessment stage I . If observed power &lt; 80 % bioequivalence evaluate stage I . If bioequivalence meet study stop bioequivalence meet , require additional patient enrol stage II . Each patient randomize one two treatment sequence ( RT TR ) accord randomization scheme prepare prior start trial . Serial blood sample determination free doxorubicin liposomal encapsulate doxorubicin plasma concentration PK analysis obtain cycle . Bioequivalence Criteria : The 94.12 % confidence interval ratio geometric least square mean ln-transformed pharmacokinetic parameter Cmax , AUC0-t AUC0-inf within 80.00 to125.00 % conclude test product bioequivalent reference product .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Female Indian Nationality , 1860n year age Able understand investigational nature study give write informed consent prior participation trial . Patients ovarian cancer require Doxorubicin whose disease progress recur platinumbased chemotherapy already receive schedule start therapy reference list drug ECOG performance status ≤ 2 Cardiac function ( LVEF ) ≥ 50 % patient life expectancy least 3 month Adequate hematopoietic , renal liver function Prior doxorubicin exposure would result total lifetime exposure 550mg/m2 four cycle treatment . Pregnant breastfeed female active opportunistic infection mycobacteria , cytomegalovirus , toxoplasma Impaired cardiac function include follow condition within past 6 month : 1 . Unstable angina 2 . QTc prolongation significant ECG abnormalities 3 . Coronary artery bypass graft surgery History hypersensitivity reaction attribute conventional formulation doxorubicin HCl component Doxorubicin Hydrochloride liposome injection . know brain metastasis HIV positive antibody syphilis Patients significantly impair hepatic function Clinically significant liver kidney disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>